Peter Lee-Armandt




Peter Lee-Armandt is a manager at Sathguru Inc, a subsidiary of Sathguru Management Consultants, India. Sathguru Inc. is a niche emerging market focused strategy and innovation advisory firm. Peter is part of healthcare practice at Boston office and advises global clients, research institutions, and entrepreneurs on innovation advancement, strategic planning and growth, and partnership opportunities in and out of emerging markets such as India and other South Asian countries.


Prior to joining Sathguru, Peter was a business development manager at GenScript USA Inc., one of the fastest growing fully integrated biology CROs. He was involved in different types of deal structures, in addition to fee-for-service, including FTE, risk sharing, and co-development. Prior to his business career, he was a scientist at Proteostasis Therapeutics, a local biotech company discovering therapeutics to control protein homeostasis. Peter received Ph.D. in neuroscience from Loyola University Chicago and completed his post-doctoral training in high-content based drug discovery from Boston University and Harvard NeuroDiscovery Center.


Sathguru Inc.

Dr. Michael Recny




Dr. Recny is a veteran drug developer with 30 years of experience in the biotechnology industry. During his career, he has contributed to the research, development and/or commercialization of three FDA approved drugs that have collectively achieved billions in worldwide sales, and to four other drug candidates that have entered human clinical trials. Dr. Recny is responsible for building and managing the portfolio of corporate risk-sharing investment partnerships for Calvert Research, and structures all investment transactions for the company.


His decades of experience in both drug development and commercialization give him the perspective needed to bridge gaps and identify innovative solutions for everyone at the table, thus leaving everyone satisfied about what they’ve achieved, and what they’ve given to close a deal. Prior to joining Calvert in 2007, Dr. Recny served in various senior leadership roles at Trimeris, Inc., Procept, Inc., and Genetics Institute, Inc. (now a division of Pfizer) where his laboratory was the first to publish the correct protein structure and biological activity of natural and recombinant human erythropoietin.



Executive VP & CIO,

Calvert Holdings and


Calvert Research

Dr. Holzbaur joined GeneChem in 1999. In 2002, she was promoted to vice president in the context of the closing of the Technologies Fund. In 2006, with the raising of the AgeChem Fund, she became General Partner. Dr. Holzbaur currently co-manages the latest Fund, AmorChem.


She has held several positions as board member of GeneChem portfolio companies in Canada, the US and Europe. Most notably, she was a member of the board of BioVex inc. and Argos Therapeutics inc. She obtained her PhD in chemistry, studying the stereospecificity of the biosynthesis of erythromycin at Cambridge University and before joining GeneChem, was a consultant in the Department of Food Science of McGill University. Her work has been published in Chemistry and Biology, the Journal of the American Chemical Society, Biochemistry and a review of infra-red spectroscopy.

Dr. Inès Holzbaur


General Partner,


(AmorChem Seed Fund)

David Gee

David has more than 25 years experience within several international healthcare companies serving in sales, marketing, international distribution, strategic planning, and business development roles. He has managed commercial activities at all stages of drug development and has extensive experience in establishing research and development collaborations, in-and out-licensing, and M&A. He has considerable product sales and marketing experience in pharmaceuticals, diagnostics and medical devices which includes management of global distribution networks.


His more recent experience spans the industry with significant experience with NCEs, NBEs Vaccines, stem cells, medical devices and diagnostics and also extends into the veterinary, nutraceutical and cosmetics sectors where he has experience of deal making with both products and technologies. Past notable experience includes management of a US$100M industrial investment fund while COO of Altana Technology Projects GmbH and senior strategic management positions with Mundipharma/Napp/Purdue Pharma, Byk Gulden, Altana Pharma, Arexis AB, Pharmexa A/S, Argenta Discovery Ltd., and MNLpharma Ltd.

Strategic Business Developer,

CATO BioVentures

Dr. Tsvetelina Lazarova

Dr. Lazarova is co-founder of MedChem partners. She has over 20 years of experience in organic chemistry, 15 of those in biotech in the Boston area. She was involved with 2 start-up companies. Dr. Lazarova received her B.A. degree in chemistry from Harvard University, M.A. in organic chemistry from MIT and PhD in organic Chemistry from University of California, Los Angeles.


MedChem Partners is a unique CRO that provides early discovery services such as solubility and pre-formulation, to encourage successful in in vitro and in vivo testing. The firm provides a number of innovative services including logistics and storage support to virtual companies as well as turnkey lab incubation space. This allows early stage entrepreneurs and start-ups to focus on proof-of-concept studies without having to invest time and money in establishing a lab and infrastructure.


MedChem Partners


Address: 9 Hamilton Place Suite 2-B, Boston, MA 02108    |    Phone: +1 (617) 600-0668    |    Email:                      © 2015 Life Science Nation